EMERCell

EMERCell is an emerging biotechnology company developing immunotherapies and cell therapies. EMERCell is developing a universal NK cell immunotherapy called NK-001. NK-001 is an optimized NK cell product designed to synergize with monoclonal antibodies (MAb) for the treatment of refractory hematologic malignancies and solid tumors.